

## Annual Declaration of Interests<sup>1</sup> (DoI) form (v2)

European Commission Initiative on Colorectal Cancer (ECICC)

Please answer each of the questions below.

If the answer to any of the questions is "Yes"<sup>2</sup>, please complete the corresponding fields, describing the circumstances, as appropriate.

If you do not submit a filled-in and signed DoI form, please consider that you cannot be involved in the current ECICC activities. If you do not disclose relevant activities of interest for the ECICC, your role may be revised.

<sup>&</sup>lt;sup>1</sup> According to European Commission's Decision C(2016) 3301 establishing horizontal rules on the creation and operation of Commission expert groups, Articles 2(4) and 11 each member of an expert group has to complete a DoI form <a href="https://ec.europa.eu/transparency/documents-register/detail?ref=C(2016)3301&lang=en">https://ec.europa.eu/transparency/documents-register/detail?ref=C(2016)3301&lang=en</a>

<sup>&</sup>lt;sup>2</sup> Answering "Yes" to the questions on this form does not automatically limit your participation in the ECICC activities. Your answers will be reviewed to determine whether you have a conflict of interest (CoI) (i.e. any interest that may affect, or may reasonably be perceived to affect, an expert's objectivity and independence).

Activities	Yes/No	Period (From - To)	Information	Details
<ul> <li>1. Do you have current investments³ in a legal entity⁴ with an interest related to colorectal cancer which either:</li> <li>• has a value of more than 10.000 EUR, or</li> <li>• entitle you to a voting right of 5% or more?</li> </ul>	Yes □ No ⊠	MM/YYYY  - MM/YYYY	If yes, please provide information about where the investment is placed (Name, Country, Public/Private).	[Please describe the entity and your role.]
2. Have you, within the last five years (January 2018 – December 2022), received remuneration from a legal entity with an interest related to colorectal cancer?				
A. Employment	Yes □ No ⊠	MM/YYYY  - MM/YYYY	<ul> <li>If yes, please specify:</li> <li>Name, Place of the entity;</li> <li>Type of the entity: public, private, etc.;</li> <li>The received amounts for remunerated activities.</li> </ul>	[Please describe your role.]

<sup>&</sup>lt;sup>3</sup> **Investments** refer to stocks, bonds, stock options, other securities as well as to commercial business interests (e.g., proprietorships, partnerships, joint ventures, board memberships, controlling interest in a company).

<sup>&</sup>lt;sup>4</sup> **Legal entity** refers to any commercial business, industry association, consultancy, research institution or other enterprise whose funding is significantly derived from commercial sources. It also includes independent own commercial businesses, law offices, consultancies or similar.

Activities	Yes/No	Period (From - To)	Information	Details
B. Consultancy, including advisory activities	Yes □ No ⊠	MM/YYYY  - MM/YYYY	If yes, please specify:  • Name, Place of the entity;  • Type of the entity: public, private, etc.;  The received amounts for remunerated activities.	Please describe your role.

Activities	Yes/No	Period (From - To)	Information	Details
3. Have you, within the past five years (January 2018 – December 2022), been involved in research related to colorectal cancer?  A. Have you been an investigator in research studies on colorectal cancer?	Yes ⊠ No □	06/2018 – 06/2019	Predictive role of faecal haemoglobin concentration among subjects with negative FIT results PI	Role: Design, analysis, drafting the report  The study aimed to estimate the predictive role of faecal haemoglobin (f-Hb) concentration among subjects with faecal immunochemical test (FIT) results below the positivity cut-off for the subsequent risk of advanced neoplasia (AN)  Senore C, et al. Faecal haemoglobin concentration among subjects with negative FIT results is associated with the detection rate of neoplasia at subsequent rounds: a prospective study in the context of population based screening programmes in Italy. Gut
		01/2019 – ongoing	Combining fecal biomarkers to improve prediction of individual's risk of pre-invasive and invasive colorectal lesions	2020; 69: 523–530  Role: Design and coordination of sturdy activities  The study aims to assess the impact of a screening protocol tailored on CRC risk, estimated based on previous screening history and to assess the potential role of fecal microbiome and miRNome profile as screening tools.

Activities	Yes/No	Period (From - To)	Information	Details
B. For the mentioned research studies, did you receive support <sup>5</sup> ?	Yes ⊠ No □	01/2019 – ongoing	<ul> <li>Grant</li> <li>AIRC (Italian association for research on cancer) Milan; private</li> <li>Overall 747,000 Euros; on average annually (over 5 years): 149,000 Euros</li> </ul>	Combining fecal biomarkers to improve prediction of individual's risk of pre-invasive and invasive colorectal lesions
		06/2018 – 06/2019	The study was conducted as a part of the routine evaluation of the screening programs performance and impact. Institutional funds.	Predictive role of faecal haemoglobin concentration among subjects with negative FIT results

\_

<sup>&</sup>lt;sup>5</sup> **Support** refers to research support (i.e. grants, collaborations, sponsorships) as well as to non-monetary support (equipment, facilities) and other type of support (i.e. honoraria for being a speaker, holding a training).

4. Do you have a membership in national or international organisations <sup>6</sup> , including committees, working groups, collaborative platforms, managing bodies or scientific advisory bodies with an interest in colorectal cancer?	Yes ⊠ No □	01/2018 – ongoing	Piedmont Region Cancer Screening Committee  Type: public.	Director of the regional cancer screening committee I am responsible for coordinating efforts aimed to standardize the methods of screening implementation, to monitor and to compare performance and results across programs, to support quality improvement, also using audit and "peer review" methods. I have been involved in the definition of the screening program protocol and I am now responsible for proposing and implementing initiatives to adapt and/or update screening protocols, to assess evidence supporting the introduction of innovative approaches and to plan cost-effectiveness evaluations
		07/2019 – ongoing	Italian Group for Colorectal cancer Screening (GISCoR)  Type: Scientific society (non- profit)	President of GISCOR, a multidisciplinary-multi-professional scientific society with a specific focus on CRC screening. The aims are to promote implementation of high quality screening interventions, training and retraining initiatives, quality assurance efforts.  I am coordinating the GISCOR activities and I am participating in defining the plans of activity
		01/2019 – ongoing	- Co-chair CRC interest group of the International Cancer Screening Network - Type: non-profit organization	Voluntary consortium of researchers, aiming to promote collaborative cancer screening research and evaluation. Group activities: planning, design and implementation of collaborative projects, involving data collection and

Activities	Yes/No	Period (From - To)	Information	Details
		06/2016 – ongoing	- World Endoscopy Organization CRC screening committee - Type: non-profit organization	analysis and drafting of methodological papers and reports.  Multidisciplinary voluntary collaborative group aiming to promote innovation, favoring translation of research evidence into practice, as well as collaboration and exchange of experiences among screening programs and initiatives, to reduce the community burden posed by CRC
		01/2018 – 12/2020	Association of European Cancer Leagues (ECL) -Type: non-profit organization	In the context of the agreement between ECL and our unit, I collaborated in providing expert technical advice in support of ECL's activities aimed to enhance access to effective and quality- controlled cancer screening programs in accordance with EU guidelines. Training on cancer screening provided through workshops and online methods

<sup>&</sup>lt;sup>6</sup> **Organisation** refers to a governmental, international or non-profit organisation.

Activities	Yes/No	Period (From - To)	Information	Details
5. Did you take part in other activities with interests related to colorectal cancer?	Yes ⊠ No □	05/2021 – ongoing	EU-TOPIA-EAST - Towards imProved screening for breast, cervical and colorectal cancer in All of Europe: (Call: H2020-SC1-2020-Single-Stage-RTD - GA n. 965014)  Canscreen - ECIS EU funded project aimed to develop and pilot a new cancer screening data management system to be integrated into the existing European Cancer Information System (ECIS).	WP leadership – monitoring Project funded by the European Commission aiming to implement effective cancer screening programs among low-middle income countries in Europe and the Mediterranean area  Work Package 3: Developing a data submission portal compliant to relevant data protection regulations to report and disseminate cancer screening performance at European level to be eventually hosted at ECIS –
6. Do you have intellectual property rights (IPR) <sup>7</sup> related to colorectal cancer?	Yes □ No ⊠	MM/YYYY  - MM/YYYY	Please specify the title of the IPR.	Please describe the IPR.
7. Do any of your immediate family members <sup>8</sup> have direct interests related to colorectal cancer that could undermine your independence?	Yes □ No ⊠	MM/YYYY  - MM/YYYY	Please mention the interest.	Please describe the interest.

<sup>&</sup>lt;sup>7</sup> **Intellectual property rights** refer to patents, trademarks, or copyrights (including pending applications) as well as proprietary know-how in a substance, technology or process. <sup>8</sup> **Immediate family members** refer to family members and relatives (spouse, parents, children, brothers and sisters, irrespective of whether they live at the same address or not) or other persons under the care of the members of the household of the expert.

## **Notes:**

If you declared any direct interests of your immediate family members, it is your responsibility to inform them about how data on their interests are collected and published<sup>9</sup> before you send the DoI form to the Joint Research Centre (JRC), European Commission.

After submission of this form, you need to inform the JRC in case of any new activity during the course of the year by sending a message as soon as possible to: <u>JRC-CANCER-POLICY-SUPPORT@ec.europa.eu</u>.

☑ I hereby declare the information disclosed in this form is true and complete to the best of my knowledge.

 $\boxtimes$  I agree my DoI form to be publicly available on the JRC Healthcare Quality website, during the European Commission Initiative on Colorectal Cancer subgroup membership<sup>10</sup>.

☑ I am informed that my personal data are stored, processed and published by the European Commission in accordance with Regulation (EU) 2018/1725<sup>11</sup>.

Name and Surname: Carlo Senore Date: 7/4/2023

Carlo Lenone

Signature: Place: Turin

<sup>&</sup>lt;sup>9</sup> Personal data processing including the Declaration of Interests https://ec.europa.eu/dpo-register/detail/DPR-EC-00656

<sup>&</sup>lt;sup>10</sup> Note: Technical measures are in place to ensure that search engines do not index the content from the DoI form.

<sup>&</sup>lt;sup>11</sup> Protection of individuals with regard to the processing of personal data https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32018R1725